SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Miscellaneous > Rigel Pharmaceuticals Inc. (RIGL)

7:40AM On The Wires (WIRES) :

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 415
Posts 22,393
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States "PR Newswire (US)" - 4/27/2017 7:30:00 AM
Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results "PR Newswire (US)" - 4/25/2017 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:56:14 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:51:45 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/21/2017 5:47:56 PM
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP "PR Newswire (US)" - 4/17/2017 4:05:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 3/29/2017 4:42:13 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 3/29/2017 4:35:36 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 3/7/2017 5:26:39 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 3/7/2017 5:02:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/7/2017 4:14:12 PM
Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update "PR Newswire (US)" - 3/7/2017 4:01:00 PM
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results "PR Newswire (US)" - 2/28/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/24/2017 5:25:44 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 2/14/2017 11:55:50 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 2/14/2017 11:31:42 AM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 2/10/2017 12:54:42 PM
Schedule 13g "Edgar (US Regulatory)" - 2/9/2017 11:00:35 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/8/2017 4:18:26 PM
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares "PR Newswire (US)" - 2/3/2017 4:01:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/31/2017 4:23:20 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 1/31/2017 4:20:44 PM
Rigel Announces Pricing Of Public Offering Of Common Stock "PR Newswire (US)" - 1/31/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/30/2017 4:40:38 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 1/30/2017 4:15:07 PM
surf1944   Friday, 05/06/11 09:58:11 AM
Re: surf1944 post# 130
Post # of 423 
7:40AM On The Wires (WIRES) :

Rigel Pharmaceuticals, Inc. (RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer (PFE) is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.



surf's up......crikey



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist